狼疮肾炎患者达到狼疮低疾病活动度后肾脏复发减少及长期肾功能得以保全
该研究纳入2010至2020年两家医院的245例狼疮肾炎患者(发现队列143例、验证队列102例),评估12个月时完全肾脏缓解(CRR)、部分肾脏缓解(PRR)、狼疮低疾病活动度状态(LLDAS)和DORIS缓解的达成情况及其与肾脏复发和肾功能保全的关系。结果显示12个月时CRR、PRR、LLDAS和DORIS缓解的达成率分别为40%、10%、49%和10%,同时达成CRR/PRR与LLDAS与最佳无复发生存相关(P < 0.001),且两者均独立降低复发风险(CRR/PRR:HR 0.31,P = 0.007;LLDAS:HR 0.38,P = 0.029)。
要点
- 12个月时狼疮肾炎患者LLDAS达成率为49%,与CRR/PRR的40%相当,提示LLDAS是可达到的治疗目标。
- 同时达成CRR/PRR与LLDAS与最佳无复发生存相关(P < 0.001),且两者均独立降低肾脏复发风险。
- LLDAS达成可预测肾功能保全,在发现队列和验证队列中ROC曲线下面积均为0.71。
核心结论
- LLDAS是狼疮肾炎可达到的治疗目标,其达成率与CRR/PRR相当,同时达成两者对降低复发风险有额外获益,早期达成LLDAS与肾功能保全相关。
研究设计与样本
- 研究纳入2010至2020年玛丽医院(发现队列)和东区尤德夫人那打素医院(验证队列)的狼疮肾炎患者,发现队列143例,验证队列102例,共245例。
- 在12个月时评估完全肾脏缓解(CRR)、部分肾脏缓解(PRR)、狼疮低疾病活动度状态(LLDAS)和SLE缓解定义(DORIS)缓解,采用回归分析识别狼疮肾炎复发的危险因素,并用ROC曲线评估目标达成与长期肾功能。
主要发现
- 12个月时,143例患者中57例(40%)达到CRR,14例(10%)达到PRR,70例(49%)达到LLDAS,15例(10%)达到DORIS缓解。
- 同时达成CRR/PRR与LLDAS与最佳无复发生存相关(P < 0.001)。
- 多变量分析显示CRR/PRR与LLDAS均独立关联狼疮肾炎复发风险降低(CRR/PRR:HR 0.31,P = 0.007;LLDAS:HR 0.38,P = 0.029)。
- LLDAS达成可预测肾功能保全,在发现队列和验证队列中ROC曲线下面积均为0.71。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Lupus low disease activity state (LLDAS) is a validated treatment target in systemic lupus erythematosus (SLE), but limited studies have explored the role of LLDAS in lupus nephritis (LN). This study aims to investigate the frequency and predictors of LLDAS attainment and its benefit on LN relapse and renal function preservation in patients with LN. METHODS: Patients with LN during 2010 to 2020 in Queen Mary Hospital and Pamela Youde Nethersole Eastern Hospital were included in the discovery cohort and validation cohort, respectively. Complete renal response (CRR), partial renal response (PRR), LLDAS, and Definition Of Remission In SLE (DORIS) remission were assessed at 12 months. Regression analysis was performed to identify risk factors of LN relapse. Receiver operating characteristic (ROC) curves were used to evaluate target attainment and long-term kidney function. RESULTS: A total of 245 patients with LN (discovery cohort n = 143 and validation cohort n = 102) were included. At 12 months, 57 of 143 (40%), 14 of 143 (10%), 70 of 143 (49%), and 15 of 143 (10%) patients achieved CRR, PRR, LLDAS, and DORIS remission, respectively. Attainment of both CRR/PRR and LLDAS at 12 months was associated with best relapse-free survival (P < 0.001). Multivariate analysis showed independent association of CRR/PRR and LLDAS with LN relapse risk reduction (CRR/PRR: hazard ratio [HR] 0.31, P = 0.007; LLDAS: HR 0.38, P = 0.029). LLDAS attainment predicts renal function preservation with satisfactory performance in both the discovery and validation cohorts (area under the curve of the ROC 0.71). CONCLUSION: LLDAS is an attainable target in LN comparable to CRR/PRR. Attainment of both targets is associated with additional benefits on relapse risk reduction. Early LLDAS attainment is associated with renal function preservation.
引用
- Cheung CK, Yap DYH, Lee KL, et al. Reduction in Renal Relapse and Preservation of Long-Term Kidney Function After Lupus Low Disease Activity in Patients With Lupus Nephritis. Arthritis Care Res (Hoboken). 2025. PMID: 40685846. doi:10.1002/acr.25611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。